Hepion Pharmaceuticals has announced that Chief Executive Officer Dr. Kaouthar Lbiati has left the company, with her departure taking effect in mid‑March and described as being for personal reasons. The board has asked existing board member Gary Stetz to assume the role of interim CEO while it considers longer‑term leadership options, and has simultaneously elevated Vincent LoPriore to executive chairman and expanded the board with two additional directors. The moves tighten board oversight and keep day‑to‑day control in the hands of familiar insiders, but they also leave investors looking for clarity on how Hepion will manage its financing needs and development priorities under this interim structure. For partners and suppliers, the leadership overhaul could temporarily slow decision‑making while also creating an opening for a broader strategic review as the refreshed board evaluates the company’s next phase.
The transition comes after a period of management turnover and strategic recalibration at Hepion, which has already prompted many stakeholders to focus more closely on governance, capital efficiency, and the future shape of its pipeline. Near term, investors are likely to scrutinize upcoming disclosures for signals on cost discipline, partnering appetite, and whether the new board composition could pave the way for business development transactions or a sharper therapeutic focus.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!